Related Experiment Video

Updated: Mar 11, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.1K

The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia

Valentín Ortíz-Maldonado1, Pablo Mozas1, Julio Delgado2

  • 1Department of Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.

Therapeutic Advances in Hematology
|December 2, 2016
PubMed

Insights

B-cell lymphoma 2 (BCL2) inhibitors show promise for treating lymphoid cancers like chronic lymphocytic leukemia (CLL). Clinical trials demonstrate their effectiveness and good safety, with potential for enhanced outcomes when combined with other therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Apoptosis, or programmed cell death, is crucial for preventing cancer development.
  • Dysregulation of the B-cell lymphoma 2 (BCL2) protein family disrupts apoptosis, contributing to cancer progression.
  • BCL2 inhibitors target this pathway, offering a novel therapeutic strategy for hematological malignancies.

Approach:

  • Investigated the role of BCL2 proteins in the mitochondrial apoptosis pathway.
  • Reviewed clinical trial data on BCL2 inhibitors in lymphoid malignancies.
  • Assessed the efficacy and toxicity profiles of BCL2 inhibitors, particularly in chronic lymphocytic leukemia (CLL).

Key Points:

  • BCL2 inhibitors are effective in treating relapsed/refractory lymphoid malignancies.
  • These agents demonstrate a favorable toxicity profile in clinical settings.
  • Combination therapies involving BCL2 inhibitors, monoclonal antibodies, and novel agents may improve treatment efficacy.

Conclusions:

  • BCL2 inhibitors represent a significant advancement in the treatment of BCL2-dependent cancers.
  • Further research into combination strategies holds promise for overcoming treatment resistance and improving patient outcomes in CLL and other lymphoid cancers.
Keywords:
B-cell lymphoma 2BH3-mimeticschronic lymphocytic leukemia

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K